Organization | Centre Hospitalier de PAU

Centre Hospitalier de PAU Report issue

Academic/Hospital Phase 2 Phase 4

Organization Overview

First Clinical Trial

2008

NCT00669149

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2020

Timeline

NOW

Now

Alternative names

Centre Hospitalier de PAU | Centre Hospitalier de Pau, Pau, France

Active Ingredients

Drugs in Phase 4 Trials (7)

acetylsalicylic acid (aspirin) (1 trial)

bivalirudin (angiomax) (1 trial)

clopidogrel (plavix) (1 trial)

enoxaparin (lovenox) (1 trial)

heparin (liquaemin) (1 trial)

protamine sulfate (1 trial)

warfarin (coumadin) (1 trial)

Drugs in Phase 2 Trials (2)

methylprednisolone (medrol) (1 trial)

rituximab (rituxan) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Coronary Artery Disease (Phase 4)

Multiple Sclerosis (Phase 2)

Multiple Sclerosis, Chronic Progressive (Phase 2)

Nervous System Diseases (Phase 2)

Sclerosis (Phase 2)

Overview

Highest Phase: Phase 4
# of Trials: 2
# of Trial APIs: 9